S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)

• W. Barcellini,
• I. Murakhovskaya,
• L. Terriou,
• F. Pane,
• A. Patriarca,
• K. Butler,
• S. Moran,
• S. Wei,
• U. Jäger

Affiliations

W. Barcellini

1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

I. Murakhovskaya

2 Albert Einstein College of Medicine/Montefiore Medical Center Bronx, New York, United States of America

L. Terriou

3 Univ. Lille, Inserm, CHU Lille, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), INFINITE – Institute for Translational Research in Inflammation, Lille, France

F. Pane

4 University of Naples “Federico II”, Naples

A. Patriarca

5 University of Eastern Piedmont and AOU “Maggiore della Carità”, Novara, Italy

K. Butler

6 Incyte Corporation, Wilmington, United States of America

S. Moran

6 Incyte Corporation, Wilmington, United States of America

S. Wei

6 Incyte Corporation, Wilmington, United States of America

U. Jäger

7 Medical University of Vienna, Vienna, Austria